COMMUNIQUÉS West-GlobeNewswire

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea
08/08/2025
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea U.S. Commercialization Officially Launched Mont-Saint-Guibert, Belgium – August 8 [...]
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
08/08/2025
Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/08/2025
CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
08/08/2025
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]
Earth Science Tech, Inc. Reports 61% Asset Growth to $7.69 Million and $8.7 Million in First Quarter Revenue Following Foundational Quarter of Strategic Acquisitions
08/08/2025
MIAMI, FL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- MIAMI, FL – August 8, 2025 – Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on acquiring and scaling high-potential [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/08/2025
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
08/08/2025
MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a [...]
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements and Implementation of Cease Trade Order
09/08/2025
Not for dissemination in the United States of America VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that the Alberta Securities [...]
XORTX Completes USD $114,500 Private Placement
09/08/2025
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 08, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX [...]
Longeveron Announces Up To $17.5 Million Public Offering
08/08/2025
$5.0 million upfront with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN [...]
Bringing Advanced Vascular Diagnostics to the Western US with the SmartVascular Dx™ Test
08/08/2025
IRVINE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC ., (“MSL” or “the Company”), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that [...]
U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
08/08/2025
This press release is not intended for UK media. HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical trial 1 Accelerated approval [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/08/2025
WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025
08/08/2025
BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its [...]
Hapbee Expands Community Monetization with Gift-A-Friend and Referral Programs
08/08/2025
Designed by Hapbee's Chief Innovation Officer and NBA Finals MVP Jaylen Brown to build upon the concept of giving, the new Gift-A-Friend and Referral Programs empower members to share wellness and earn rewards directly [...]
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
08/08/2025
WARREN, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced an update on institutional ownership of the Company’s outstanding common stock, as [...]
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
08/08/2025
Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of [...]
Spectral Medical Announces Second Quarter and Provides Corporate Update
08/08/2025
Topline Tigris results expected to be released around mid-August 2025 TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing [...]
Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results
08/08/2025
Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis (1) , compared to Q2 2024 Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0 [...]

Pages